Keloids-Pipeline Review, H2 2016

Keloids-Pipeline Review, H2 2016


  • Products Id :- GMDHC8893IDB
  • |
  • Pages: 53
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Keloids-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids-Pipeline Review, H2 2016, provides an overview of the Keloids (Keloids) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keloids (Keloids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Keloids) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Keloids (Keloids) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Keloids).

The pipeline guide reviews pipeline therapeutics for Keloids (Keloids) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Keloids (Keloids) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Keloids (Keloids) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Keloids)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Keloids (Keloids).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Keloids (Keloids) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Keloids Overview 6

Therapeutics Development 7

Pipeline Products for Keloids-Overview 7

Pipeline Products for Keloids-Comparative Analysis 8

Keloids-Therapeutics under Development by Companies 9

Keloids-Therapeutics under Investigation by Universities/Institutes 10

Keloids-Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Keloids-Products under Development by Companies 13

Keloids-Products under Investigation by Universities/Institutes 14

Keloids-Companies Involved in Therapeutics Development 15

FirstString Research Inc 15

RXi Pharmaceuticals Corp 16

Topadur Pharma AG 17

Tumorend LLC 18

viDA Therapeutics Inc 19

Yuhan Corp 20

Keloids-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

CM-101-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Granexin-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

koebnerisin-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

psoriasin-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

RXI-109-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

TOPN-44-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

V-2248-Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

VTI-3000 Series-Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

YH-siRNA1-Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Keloids-Dormant Projects 45

Keloids-Discontinued Products 46

Keloids-Product Development Milestones 47

Featured News & Press Releases 47

Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 47

Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 47

Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 48

Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 48

Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 49

Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 49

Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 50

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Figures

Number of Products under Development for Keloids, H2 2016 7

Number of Products under Development for Keloids-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Targets, H2 2016 22

Number of Products by Stage and Targets, H2 2016 22

Number of Products by Mechanism of Actions, H2 2016 24

Number of Products by Stage and Mechanism of Actions, H2 2016 24

Number of Products by Routes of Administration, H2 2016 26

Number of Products by Stage and Routes of Administration, H2 2016 26

Number of Products by Molecule Types, H2 2016 28

Number of Products by Stage and Molecule Types, H2 2016 28

List of Tables

Number of Products under Development for Keloids, H2 2016 7

Number of Products under Development for Keloids-Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Keloids-Pipeline by FirstString Research Inc, H2 2016 15

Keloids-Pipeline by RXi Pharmaceuticals Corp, H2 2016 16

Keloids-Pipeline by Topadur Pharma AG, H2 2016 17

Keloids-Pipeline by Tumorend LLC, H2 2016 18

Keloids-Pipeline by viDA Therapeutics Inc, H2 2016 19

Keloids-Pipeline by Yuhan Corp, H2 2016 20

Assessment by Monotherapy Products, H2 2016 21

Number of Products by Stage and Target, H2 2016 23

Number of Products by Stage and Mechanism of Action, H2 2016 25

Number of Products by Stage and Route of Administration, H2 2016 27

Number of Products by Stage and Molecule Type, H2 2016 29

Keloids-Dormant Projects, H2 2016 45

Keloids-Discontinued Products, H2 2016 46

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

FirstString Research Inc, RXi Pharmaceuticals Corp, Topadur Pharma AG, Tumorend LLC, viDA Therapeutics Inc, Yuhan Corp

Keloids Therapeutic Products under Development, Key Players in Keloids Therapeutics, Keloids Pipeline Overview, Keloids Pipeline, Keloids Pipeline Assessment

select a license

Single User License
USD 2000 INR 129560
Site License
USD 4000 INR 259120
Corporate User License
USD 6000 INR 388680

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com